Tuesday, December 21, 2021 4:06:51 PM
https://www.korumedical.com/investors/news-events/press-releases/detail/106/koru-medical-systems-receives-fda-510k-clearance-for-the
CHESTER, N.Y.--(BUSINESS WIRE)-- Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use home infusion solutions, today announced FDA 510(k) clearance that expands on-label use of the FREEDOM60 Infusion System to two additional subcutaneous Ig (SCIg) medications, Cutaquig®, manufactured by Octapharma, and Xembify®, manufactured by Grifols.
“We are excited to announce another milestone for KORU Medical as we seek to further improve patients’ quality of life through the development and delivery of high-quality therapeutic drug delivery in the home. Having the FREEDOM60 Infusion System cleared for use with Xembify and Cutaquig allows patients and providers additional options for life enhancing subcutaneous immunoglobulin therapy treatment in the home with a system that has broad patient and healthcare worker adoption,” said Linda Tharby, President and CEO. “KORU Medical’s Freedom Infusion System is specifically cleared for use with more SCIg drugs than any other system. Adding Xembify and Cutaquig to our label, in addition to our recent FDA 510(k) clearance for use of Hizentra® prefilled syringes with the FreedomEdge®, extends KORU Medical’s leadership position in the growing SCIg market.”
Recent KRMD News
- KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth • Business Wire • 05/01/2024 08:05:00 PM
- KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024 • Business Wire • 04/17/2024 11:00:00 AM
- KORU Medical Systems Announces Successful Appeal in EU Notified Body Review • Business Wire • 04/11/2024 08:05:00 PM
- KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference • Business Wire • 03/18/2024 09:24:00 PM
- KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance • Business Wire • 03/13/2024 08:05:00 PM
- KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic • Business Wire • 03/11/2024 08:05:00 PM
- KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin • Business Wire • 03/06/2024 12:00:00 PM
- KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 • Business Wire • 02/21/2024 12:00:00 PM
- KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference • Business Wire • 11/29/2023 12:00:00 PM
- KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023 • Business Wire • 11/28/2023 01:00:00 PM
- KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System • Business Wire • 11/08/2023 09:10:00 PM
- KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer • Business Wire • 11/08/2023 09:08:00 PM
- KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 11/08/2023 09:05:00 PM
- KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes • Business Wire • 11/07/2023 09:05:00 PM
- KORU Medical Systems to Participate in Upcoming Investor Conferences • Business Wire • 11/02/2023 08:05:00 PM
- KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023 • Business Wire • 10/25/2023 08:05:00 PM
- KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference • Business Wire • 10/05/2023 11:05:00 AM
- KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors • Business Wire • 10/04/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase • Business Wire • 09/15/2023 12:05:00 PM
- KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 08/09/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference • Business Wire • 08/08/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates • Business Wire • 08/02/2023 09:15:00 PM
- KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023 • Business Wire • 07/31/2023 08:05:00 PM
- KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic • Business Wire • 07/27/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes • Business Wire • 07/10/2023 11:01:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM